Alligator Bioscience AB (publ) Interim report January-March 2020
Stronger focus on clinical projects "The focusing of our operations protects the company’s liquidity, but is also part of our long-term ...
Alligator Bioscience increases focus on clinical development
Lund, Sweden, 7 April 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today that the company has decided to increase its fo ...
Alligator Bioscience informs about temporary halt of recruitment of new patients due to the covid-19 pandemic
Lund, Sweden, 1 April 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), announced today a temporary halt in the recruitment of new pati ...
Alligator Bioscience’s Annual Report 2019 published
Lund, Sweden, 2 March 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutica ...
Alligator Bioscience AB Year-end Report January-December 2019
"2019 was the year when Alligator entered the clinical phase on a broad front. At the beginning of the year, we had one clinical project ...
Alligator Bioscience AB Interim report January-September 2019
"We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 su ...
Alligator Bioscience signs antibody agreement for Greater China with Biotheus Inc.
Lund, Sweden, August 20, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that a license agreement has been reached wi ...
Alligator Bioscience regains global rights from Janssen to CD40 agonistic antibody, ADC-1013 (JNJ-64457107)
Lund, Sweden, July 31, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that it has regained exclusive, worldwide righ ...
Alligator Bioscience AB (publ) Interim report January-June 2019
Competitive safety data for ADC-1013. Significant events April-June• Janssen presented data from the clinical Phase I study with ADC-1013 in ...